Cardiomyopathy, HypertrophicRENOMICA-HcorNCT06546137

National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry

An observational study of Cardiomyopathy, Hypertrophic and Cardiomyopathy, Dilated, run by Hospital do Coracao at 27 sites in Brazil.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are: Which genes are most commonly affected? What is the frequency of these genetic alterations in our population?… Read more about this study

Who is it for?: Any age
Conditions the study is for: Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated, Cardiomyopathy Restrictive
What is being tested?: whole genome sequencing
How many people: 1,211 participants
Where: 27 sitesBrazil
Study dates: 30 Apr 2025to 31 Aug 2026
How long will I take part?: 6 Months
Phase: Observational
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages Any age
All sexes
No healthy volunteers
Child, Adult, Older adult

Study population: Patients under routine medical care in hospitals and clinics located in Brazil with a clinical diagnosis of an hereditary cardiovascular disease.

Who may be able to join

Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines
Agree to receive genetic counseling
Sign informed consent form
Provide the information required in the case report form

Who cannot join

Signature absent from informed consent form
Inadequate buccal swab (sample may be collected twice)

Trial locations and contacts

27 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Adriana Bastos Carvalho, MD PhD contact

+552130372105

carvalhoab@biof.ufrj.br

City, postcode or hospital

Sites recruiting now only

27 sites in 1 country

Brazil27 sites, 27 recruiting

Health & Care
Belém, Pará, 66093-055
Jonathan S. Sarraf, +5591980295594, jonathansouzasarraf@gmail.com
Jonathan S. Sarraf
Recruiting
Hospital Felicio Rocho - HFR
Belo Horizonte, Minas Gerais, 30110-934
Maria da Consolação Vieira Moreira, +553135147000, mariacvmoreira@gmail.com
Maria da Consolação Vieira Moreira
Recruiting
Liga Mineira de Ressuscitação Cardiopulmonar
Belo Horizonte, Minas Gerais, 30130-110
Eduardo Back Stenick, +553132130004, eduardosternick@gmail.com
Eduardo Back Stenick
Recruiting
Hospital Universitário São Francisco na Providência de Deus, USF-SP
Bragança Paulista, São Paulo, 12916-542
Murillo O. Antunes, +551124901130, dr.murilloantunes@gmail.com
Murillo O. Antunes
Recruiting
Instituto de Cardiologia e Transplantes do Distrito Federal
Brasília, Federal District, 70675-731
Cristina Machado Camargo Afiune, +556134511000, cris.afiune@gmail.com
Cristina Machado Camargo Afiune
Recruiting
Instituto PENSI
Consolação, São Paulo, 01228-200
Mauro Fisberg, +551195776-9213, mauro.fisberg@gmail.com
Mauro Fisberg
Recruiting
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Fortaleza, Ceará, 60840-285
Sônia Maria Cavalcante da Rocha, +558531014151, sonia.mrcavalcante@gmail.com
Sônia Maria Cavalcante da Rocha
Recruiting
Hospital das Clínicas da Universidade Federal de Goiás - HC-UFG
Goiânia, Goiás, 74605-050
Weimar Kunz Sebba Barroso de Souza, +556232698200, sebbabarroso@gmail.com
Weimar Kunz Sebba Barroso de Souza
Recruiting
Centro Multidisciplinar de Ensino Especializado e Pesquisa Ltda
Joinville, Santa Catarina, 89204-250
Kárila Scarduelli Luciano, +5547992007079, karilasl@gmail.com
Kárila Scarduelli Luciano
Recruiting
Hospital Universitário da Unifap
Macapá, Amapá, 68903-419
Álan B. F. Rebelo, +559632136100, alan.rebelo@ebserh.gov.br
Álan B. F. Rebelo
Recruiting
Centro de Pesquisas Clínicas Dr. Marco Mota
Maceió, Alagoas, 57051-160
Marco Antonio Mota Gomes, +558232155066, mota-gomes@uol.com.br
Marco Antonio Mota Gomes
Recruiting
Santa Casa de Misericórdia de Montes Claros
Montes Claros, Minas Gerais, 39401-001
Luciano Freitas Fernandes, +553832248000, luclucianofreitas@yahoo.com.br
Luciano Freitas Fernandes
Recruiting
Hospital Universitário Onofre Lopes - UFRN
Natal, Rio Grande do Norte, 59012-300
Rosiane Viana Zuza Diniz, +558433425000, rosianevzdiniz@gmail.com
Rosiane Viana Zuza Diniz
Recruiting
Universidade Federal do Tocantins
Palmas, Tocantins, 77001-090
Luciana Carla Holzbach, +556332294350, luciana.carla@mail.uft.edu.br
Luciana Carla Holzbach
Recruiting
Hospital das Clínicas de Porto Alegre - UFRGS
Porto Alegre, Rio Grande do Sul, 90035-903
Fabiano de Oliveira Poswar, +555133598000, fposwar@hcpa.edu.br
Fabiano de Oliveira Poswar
Recruiting
Instituto de Cardiologia - Fundação Universitária de Cardiologia de Porto Alegre - IC-FUC
Porto Alegre, Rio Grande do Sul, 90040-370
Maico Furlanetto, +555132303600, maicofurlanetto@gmail.com
Maico Furlanetto
Recruiting
Instituto de Pesquisa e Ensino em Saúde - IPES
Porto Velho, Rondônia, 76801-098
Mariana Pinheiro Alves Vasconcelos, +5569993787257, dbpfall@gmail.com
Mariana Pinheiro Alves Vasconcelos
Recruiting
Centro de Pesquisa Silvestre Santé
Rio Branco, Acre, 69915-030
Odilson Marcos Silvestre, +5568999211100, odilsonms@gmail.com
Odilson Marcos Silvestre
Recruiting
Hospital Universitário Pedro Ernesto - UERJ
Rio de Janeiro, Rio de Janeiro, 20551-030
Marcelo Imbroinise Bittencourt, +552128688000, marcelo.bittencourt@hupe.uerj.br
Marcelo Imbroinise Bittencourt
Recruiting
Instituto de Puericultura e Pediatria Martagão Gesteira
Rio de Janeiro, Rio de Janeiro, 21941-912
Nathalie J. M. Bravo Valenzuela, +552139384816, njmbravo@cardiol.br
Nathalie J. M. Bravo Valenzuela
Recruiting
Hospital Universitário Clementino Fraga Filho - UFRJ
Rio de Janeiro, Rio de Janeiro, 21941-913
Tais Hanae Kasai Brunswick, +552139382789, kasaitais@biof.ufrj.br
Tais Hanae Kasai Brunswick
Recruiting
Instituto Nacional de Cardiologia
Rio de Janeiro, Rio de Janeiro, 22240-006
Helena Cramer Veiga Rey, MD PhD, +552130372105, hcramer0504@gmail.com
Helena Cramer Veiga Rey
Recruiting
Hospital Universitário Professor Edgard Santos
Salvador, Estado de Bahia, 40110-060
Luiz Pereira de Magalhães, MD PhD, +557136463400, luizmagalhaes12@gmail.com
Luiz Pereira de Magalhães
Recruiting
Hospital Ana Nery - HAN/SESAB
Salvador, Estado de Bahia, 40320-010
Mauricio Alves Barreto, +557131171800, mauricioabarreto@uol.com.br
Mauricio Alves Barreto
Recruiting
Hospital Universitário da Universidade Federal de São Carlos
São Carlos, São Paulo, 13566-448
Meliza Roscani, +551635092400, meliza.roscani@ufscar.br
Meliza Roscani
Recruiting
Hospital do Coracao
São Paulo, São Paulo, 04004-030
Otavio Eboli, +551130536611, ceclin.cardio@outlook.com
Otavio Eboli
Recruiting
Hospital Evangélico de Vila Velha
Vila Velha, Espírito Santo, 29118-060
Carina Laranja Mattos Barreto, +552799513-6656, claranjamattos@gmail.com
Carina Laranja Mattos Barreto
Recruiting

Other trials in Brazil

About this study

Which genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.

Conditions: Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated, Cardiomyopathy Restrictive, Arrhythmogenic Right Ventricular Dysplasia, Non-Compaction Cardiomyopathy, Familial Hypercholesterolemia
Being tested: whole genome sequencing
Keywords: hereditary cardiovascular diseases, whole genome sequencing
Medical subject headings: Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated, Cardiomyopathy, Restrictive, Arrhythmogenic Right Ventricular Dysplasia, Hyperlipoproteinemia Type II, Marfan Syndrome, Ehlers-Danlos Syndrome, Type IV, Loeys-Dietz Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

whole genome sequencingDiagnostic test
whole genome sequencing of genomic DNA extracted from buccal swab

What is being measured

The primary outcome is the main question the study is designed to answer.

Diagnostic yield
Percentage of participants with pathogenic or likely pathogenic variants
Measured: 30 months after study start date
Genetic diversity
Determine genes that cause hereditary cardiovascular diseases in Brazil
Measured: 30 months after study start date
Variant frequency
Determine the frequency of disease-causing and benign variants in the Brazilian population
Measured: 30 months after study start date

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Apr 202531 Aug 2026

First posted9 Aug 2024
Study start30 Apr 2025
Primary completion31 Aug 2026 (estimated)
Study completion31 Aug 2026 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Cardiomyopathy, HypertrophicStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Family based
Time perspective: Prospective
Enrolment: 1,211 participants (estimated)
Target duration: 6 Months

IDs, dates and publications

ClinicalTrials.gov ID: NCT06546137
Sponsor's protocol ID: RENOMICA-Hcor
Acronym: RENOMICA-Hcor
Status last verified: Nov 2025
First submitted: 6 Aug 2024
Last updated: 8 May 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No: Genomic data are sensitve and will not be shared for individual participants

Interested in taking part?

Adriana Bastos Carvalho, MD PhD

+552130372105

carvalhoab@biof.ufrj.br

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
RecruitingPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Nonobstructive Hypertrophic Cardiomyopathy
Recruiting
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction
RecruitingObservational study
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
Coronary Artery Disease, Myocarditis

All Cardiomyopathy, Hypertrophic trials

Study at a glance

From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
ClinicalTrials.gov ID: NCT06546137
Acronym / sponsor ID: RENOMICA-Hcor / RENOMICA-Hcor
Conditions: Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated, Cardiomyopathy Restrictive, Arrhythmogenic Right Ventricular Dysplasia, Non-Compaction Cardiomyopathy, Familial Hypercholesterolemia
Keywords: hereditary cardiovascular diseases, whole genome sequencing
Study type: Observational
Recruitment status: Recruiting
Enrolment: 1,211 participants (estimated)
Lead sponsor: Hospital do CoracaoUniversity, hospital or other
Collaborators: Instituto Nacional de Cardiologia de Laranjeiras, Universidade Federal do Rio de Janeiro
Study start: 30 Apr 2025 (actual)
Primary completion: 31 Aug 2026 (estimated)
Study completion: 31 Aug 2026 (estimated)
First posted: 9 Aug 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model: Family based
Time perspective: Prospective
Target follow-up: 6 Months

Who may qualify

Sex: All
Healthy volunteers: Not accepted
Age groups: Child, Adult, Older adult
Study population: Patients under routine medical care in hospitals and clinics located in Brazil with a clinical diagnosis of an hereditary cardiovascular disease.

Key inclusion criteria (4 listed)

Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines
Agree to receive genetic counseling
Sign informed consent form
Provide the information required in the case report form

Key exclusion criteria (2 listed)

Signature absent from informed consent form
Inadequate buccal swab (sample may be collected twice)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
whole genome sequencingwhole genome sequencing of genomic DNA extracted from buccal swab	Diagnostic test	–

Primary outcome

Diagnostic yield
Time frame: 30 months after study start date
Percentage of participants with pathogenic or likely pathogenic variants
Genetic diversity
Time frame: 30 months after study start date
Determine genes that cause hereditary cardiovascular diseases in Brazil
Variant frequency
Time frame: 30 months after study start date
Determine the frequency of disease-causing and benign variants in the Brazilian population

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
Individual participant dataSharing planned: No. Genomic data are sensitve and will not be shared for individual participants

Related trials for Cardiomyopathy, Hypertrophic

Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
RecruitingPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Nonobstructive Hypertrophic Cardiomyopathy
Recruiting
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction
RecruitingObservational study
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
Coronary Artery Disease, Myocarditis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Adriana Bastos Carvalho, MD PhD contact

+552130372105

carvalhoab@biof.ufrj.br

27 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiomyopathy, Hypertrophic and Cardiomyopathy, Dilated, run by Hospital do Coracao at 27 sites in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 27 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Adriana Bastos Carvalho, MD PhD (+552130372105, carvalhoab@biof.ufrj.br), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic yield (time frame: 30 months after study start date). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06546137.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.